Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
4.450
-0.200 (-4.30%)
At close: Sep 18, 2026, 4:00 PM EDT
4.530
+0.080 (1.80%)
After-hours: Sep 18, 2026, 7:30 PM EDT
Verrica Pharmaceuticals Employees
Verrica Pharmaceuticals had 76 employees as of December 31, 2025. The number of employees increased by 5 or 7.04% compared to the previous year.
Employees
76
Change (1Y)
5
Growth (1Y)
7.04%
Revenue / Employee
$398,961
Profits / Employee
-$410,303
Market Cap
76.45M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 76 | 5 | 7.04% |
| Dec 31, 2024 | 71 | -29 | -29.00% |
| Dec 31, 2023 | 100 | 78 | 354.55% |
| Dec 31, 2022 | 22 | -16 | -42.11% |
| Dec 31, 2021 | 38 | 9 | 31.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pelthos Therapeutics | 92 |
| Fortress Biotech | 78 |
| Connect Biopharma Holdings | 64 |
| iBio, Inc. | 23 |
| Gain Therapeutics | 21 |
| Cingulate | 14 |
| OS Therapies | 5 |
| NeOnc Technologies Holdings | 5 |
VRCA News
- 4 days ago - Verrica Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 4 days ago - Verrica Pharmaceuticals Slides: Corporate presentation - Filings
- 8 days ago - Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences - GlobeNewsWire
- 10 days ago - Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 22 days ago - Lake Street starts Verrica Pharmaceuticals with a Buy - TheFly
- 22 days ago - Verrica Pharmaceuticals initiated with a Buy at Lake Street - TheFly
- 22 days ago - Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027 - GlobeNewsWire
- 4 weeks ago - Verrica Pharmaceuticals CEO buys $125.8K in common stock - TheFly